Maraviroc -: Anti-HIV agent viral entry inhibitor chemokine CCR5 antagonist

被引:8
|
作者
Ginesta, JB [1 ]
Castañer, J [1 ]
Bozzo, J [1 ]
Bayés, M [1 ]
机构
[1] Prous Sci, Barcelona 08080, Spain
关键词
4,4-difIuoro-N-[3-[(1R,3exo,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropy])cyclohexanecarboxamide;
D O I
10.1358/dof.2005.030.05.902712
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite the availability of several approved drugs for the treatment of human immunodeficiency virus (HIV) infection, the limited effectiveness of current antiretroviral regimens, mainly due to the emergence of resistance, makes the development of new agents necessary. Several novel compounds are being added to existing classes, but newer classes of antiretroviral drugs, such as HIV entry inhibitors, are also under development. Maraviroc is a novel small molecule that specifically antagonizes the chemokine CCR5 receptor required for efficient HIV entry. It displays potent and broad-spectrum anti-HIV activity and excellent pharmacokinetic and safety profiles. All these features and the promising results obtained in early clinical trials make this agent a good candidate for inclusion in combination therapies for HIV treatment. Maraviroc is the most clinically advanced CCR5 antagonist and has just entered phase III clinical trials.
引用
收藏
页码:469 / 477
页数:9
相关论文
共 50 条
  • [21] Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA)
    Polianova, MT
    Ruscetti, FW
    Pert, CB
    Ruff, MR
    ANTIVIRAL RESEARCH, 2005, 67 (02) : 83 - 92
  • [22] Potent Anti-HIV Chemokine Analogs Direct Post-Endocytic Sorting of CCR5
    Boensch, Claudia
    Munteanu, Mihaela
    Rossitto-Borlat, Irene
    Fuerstenberg, Alexandre
    Hartley, Oliver
    PLOS ONE, 2015, 10 (04):
  • [23] The role of CCR5 and other chemokine receptors in HIV entry.
    Blanpain, C
    Libert, F
    Lee, B
    Vakili, J
    Migeotte, I
    Govaerts, C
    Maho, A
    Samson, M
    Doranz, B
    Rucker, J
    Detheux, M
    Vassart, G
    Doms, RW
    Parmentier, M
    BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 : U117 - U117
  • [24] Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii
    Yarovinsky, F
    Andersen, JF
    King, LR
    Caspar, P
    Aliberti, J
    Golding, H
    Sher, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (51) : 53635 - 53642
  • [25] Small Molecule CCR5 and CXCR4-Based Viral Entry Inhibitors for Anti-HIV Therapy Currently in Development
    Kazmierski, Wieslaw M.
    Gudmundsson, Kristjan S.
    Piscitelli, Stephen C.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 42, 2007, 42 : 301 - 320
  • [26] Update on aplaviroc: An HIV entry inhibitor targeting CCR5
    Demarest, James F.
    RETROVIROLOGY, 2005, 2 (Suppl 1)
  • [27] Maraviroc, a CCR5 Coreceptor Antagonist That Blocks Entry of Human Immunodeficiency Virus Type 1
    Hunt, Joshua S.
    Romanelli, Frank
    PHARMACOTHERAPY, 2009, 29 (03): : 295 - 304
  • [28] Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
    Lorenzen, Thore
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2010, 2 : 151 - 156
  • [29] Update on Aplaviroc: An HIV Entry Inhibitor Targeting CCR5
    James F Demarest
    Retrovirology, 2
  • [30] Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay
    van der Ryst, Elna
    Heera, Jayvant
    Demarest, James
    Knirsch, Charles
    COMPANION DIAGNOSTICS: FROM BIOMARKER IDENTIFICATION TO MARKET ENTRY, 2015, 1346 : 7 - 17